Taken together, these clinical trials shed light on the importance of IL6, TGFβ, CXCR4, and CD40 in cancer treatment, as well as their potential therapeutic effects on pancreatic cancer. This evidence concerns the gene TGFB1 and familial pancreatic carcinoma.